Glycopyrrolate bromide - CAS 596-51-0
Catalog number: 596-51-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C19H28BrNO3
Molecular Weight:
398.33
COA:
Inquire
Targets:
mAChR
Description:
Glycopyrrolate bromide is a muscarinic competitive antagonist used as an antispasmodic.
Purity:
>98%
Synonyms:
Glycopyrrolate; GLYCOPYRROLATE; Glycopyrronium bromide; Glycopyrrolate bromide; Robinul; Gastrodyn; Asecryl; NVA 237; NVA-237; NVA237;
MSDS:
Inquire
InChIKey:
VPNYRYCIDCJBOM-UHFFFAOYSA-M
InChI:
InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1
Canonical SMILES:
C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
1.Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Horita N1, Kaneko T1. Int J Chron Obstruct Pulmon Dis. 2015 Apr 21;10:813-22. doi: 10.2147/COPD.S56067. eCollection 2015.
Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device (Ultibro, Breezhaler), often called QVA149, was first approved in 2013 in Japan and Europe. As of November 2014, more than 40 countries had approved this medication except for the USA. This is the first dual bronchodilator in one device. Now, the Breezhaler is the only device that can provide long-acting muscarinic antagonist (glycopyrronium bromide), long-acting beta agonist (indacaterol), and a combination of the two medications (QVA149). The choice among the three medications allows a patient to use the same inhalation device even when the regimen is changed from single-bronchodilator therapy to dual-bronchodilator therapy. In addition, the quick bronchodilation effect and once-daily administration can improve patient adherence to medical treatment for chronic obstructive pulmonary disease (COPD). To our knowledge, as of November 2014, the safety and the efficacy of QVA149 have been evaluated in 14 randomized controlled trials.
2.Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Prakash A1, Babu KS2, Morjaria JB3. Int J Chron Obstruct Pulmon Dis. 2015 Jan 7;10:111-23. doi: 10.2147/COPD.S67758. eCollection 2015.
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality. The cornerstone of pharmacological treatment for COPD is bronchodilation. Inhaled glycopyrronium bromide is a long-acting muscarinic antagonist developed as a maintenance treatment for patients with COPD. Phase III trials have shown that glycopyrronium produces rapid and sustained bronchodilation with an efficacy similar to tiotropium and is well tolerated, with a low incidence of muscarinic side effects in patients with moderate to severe COPD. A combination of glycopyrronium bromide with indacaterol maleate (QVA149) has recently been approved as a once-daily maintenance therapy in adult patients with COPD. Phase III trials (the IGNITE program) with QVA149 have demonstrated significant improvements in lung function versus placebo, glycopyrronium, and tiotropium in patients with moderate to severe COPD, with no safety concerns of note. Hence QVA149 is a safe treatment option for moderate to severe COPD patients in whom long-acting muscarinic antagonist monotherapy is inadequate.
3.Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R1, Gessner C2, Schuermann W3, Foerster K4, Sieder C5, Hiltl S5, Korn S6. Thorax. 2015 Apr;70(4):311-9. doi: 10.1136/thoraxjnl-2014-206345. Epub 2015 Feb 12.
BACKGROUND: QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD.
4.Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E1, Montagni M1, Riario-Sforza GG2, Baroni M2, Incorvaia C3. Ther Adv Respir Dis. 2015 Apr;9(2):49-55. doi: 10.1177/1753465815572065. Epub 2015 Feb 17.
The international guidelines on chronic obstructive pulmonary disease (COPD) recommend inhaled bronchodilators for maintenance treatment of the disease. These drugs include β2-agonists and muscarinic antagonists, which are both available as short-acting agents (to be used as needed for dyspnea) and long-acting agents. To the latter belong salmeterol and formoterol (long-acting β2-agonists) and indacaterol, vilanterol and olodaterol (very long-acting β2-agonist) as β2-agonists, and tiotropium, aclidinium and glycopyrronium bromide as long-acting muscarinic antagonists. The efficacy and safety of indacaterol and glycopyrronium as monotherapies has been demonstrated in several controlled trials. However, in some patients with moderate-to-severe COPD, symptoms are poorly controlled by bronchodilator monotherapy; in these cases the addition of a second bronchodilator from a different pharmacological class may be beneficial. Here we review the evidence from published randomized trials concerning the efficacy and safety of the once-daily fixed-dose dual bronchodilator combining indacaterol and glycopyrronium.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mAChR Products


CAS 3717-88-2 Flavoxate hydrochloride

Flavoxate hydrochloride
(CAS: 3717-88-2)

Flavoxate is an anticholinergic with antimuscarinic effects. Its muscle relaxant properties may be due to a direct action on the smooth muscle rather than by an...

CAS 107220-28-0 Cevimeline hydrochloride

Cevimeline hydrochloride
(CAS: 107220-28-0)

Cevimeline hydrochloride is a selective M1 receptor agonist.

CAS 300-08-3 Arecoline hydrobromide

Arecoline hydrobromide
(CAS: 300-08-3)

Arecoline is a muscarinic acetylcholine receptor agonist.

CAS 633283-39-3 VU 10010

VU 10010
(CAS: 633283-39-3)

VU 10010 is a selective allosteric potentiator at M4 acetylcholine receptors (EC50 = 33 and 0.7 nM for ACh in the absence and presence of VU10010 respectively)....

CAS 596-51-0 Glycopyrrolate bromide

Glycopyrrolate bromide
(CAS: 596-51-0)

Glycopyrrolate bromide is a muscarinic competitive antagonist used as an antispasmodic.

CAS 71-81-8 Isopropamide Iodide

Isopropamide Iodide
(CAS: 71-81-8)

Isopropamide Iodide is an anticholinergic compound and a muscarinic receptor antagonist, which can be used for Alzheimer's disease treatment.

CAS 107233-08-9 Cevimeline

Cevimeline
(CAS: 107233-08-9)

Cevimeline is a selective M1 receptor agonist.

CAS 590-63-6 Bethanechol Chloride

Bethanechol Chloride
(CAS: 590-63-6)

A selective muscarinic receptor stimulant, used to treat cerebral palsy.

Chemical Structure

CAS 596-51-0 Glycopyrrolate bromide

Quick Inquiry

Verification code

Featured Items